Seeking Alpha

Move over Vascepa, here comes Epanova

  • The FDA approves AstraZeneca's (AZN) Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (>=500 mg/dl). It is the first approved omega-3 in free fatty acid form. Patients can take as few as two capsules/day.
  • In some patients Epanova increases LDL-Cholesterol so this parameter should be monitored periodically during therapy. This will undoubtedly be a selling point for Amarin's (AMRN) Vascepa (icosapent ethyl) since it lowers LDL-C.
  • (OMTH)
Comments (7)
  • steppppo
    , contributor
    Comments (214) | Send Message
     
    Nice. Now, we just need the exclusivity determination to be reached by September 30, 2014 for the first milestone payment. At least, I think that's what we're waiting for.
    6 May, 09:16 AM Reply Like
  • ralphey
    , contributor
    Comments (322) | Send Message
     
    Yea move over for a product that has that raises ldl - dont think so !
    6 May, 12:42 PM Reply Like
  • stevie.atl
    , contributor
    Comments (24) | Send Message
     
    Interesting. So if, as the FDA claimed with Amarin’s rejected attempt at label expansion, there is no evidence that lowering TGs reduces CV events, why is the FDA approving yet another fish oil medication that lowers TGs???
    6 May, 01:26 PM Reply Like
  • Not_Quite_Pheidippides
    , contributor
    Comments (147) | Send Message
     
    Very high triglycerides increase the risk of pancreatitis. That's essentially why the FDA will keep approving TG-lowering drugs for the MARINE population, but not ANCHOR (those levels not well associated with pancreatitis, I believe, but correct me if I'm wrong).
    8 May, 10:43 AM Reply Like
  • stevie.atl
    , contributor
    Comments (24) | Send Message
     
    Perhaps that's the reason, but as far as I know, these products aren't marketed as a treatment or prevention for pancreatitis. It seems to me that the same specious arguments the FDA made against Vascepa's label expansion and in the inexplicable rescinding of the Anchor SPA should apply equally to the approval decision for Epanova....if the FDA operated on the basis of consistency, which they clearly do not.
    8 May, 12:10 PM Reply Like
  • mitrado
    , contributor
    Comments (1948) | Send Message
     
    The FDA only cares about the big multinationals and that's why I've stopped trading biostocks. No point in betting against "the house."
    9 May, 06:22 AM Reply Like
  • mitrado
    , contributor
    Comments (1948) | Send Message
     
    FDA corruption proved once again.
    7 May, 03:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|